Considering the role of YAP/TAZ in forming physical and immunosuppressive barriers, YAP pathway inhibition could enhance chimeric antigen receptor (CAR)-T cell therapy by remodeling the TME, sensitizing tumor cells to immune killing and improving CAR-T function. The gene discussed is YAP1; the disease is neoplasm.